 Home > Active Ingredient News > Antitumor Therapy > Roche's Tecentriq/Avastin combination gets U.S. approval - the first immunotherapy for cancer that cannot be removed or metastatic

Roche's Tecentriq/Avastin combination gets U.S. approval - the first immunotherapy for cancer that cannot be removed or metastatic

 Last Update: 2020-06-05
 Source: Internet
 Author: User

Tags

cialis medicine

ancient roman medicine

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

U.Sregulators have approved a combination of Roche's PD-L1 monosero-tecentriq (atezolizumab) and anti-angiotherite-based monoserotrophilia monovastin (bevacionzumab) to treat unable to remove or metastatic hepatocellular carcinoma (HCC) without systemic treatmentthe approval, which makes Tecentriq in conjunction with Avastin the first and only FDA-approved cancer immunotherapy for cancer that cannot be removed or metastaticapproved the results of the Phase III IMbrave150 study, which showed that the combination of Tecentriq and Avastin reduced the risk of death by 42 percent and the risk of disease deterioration or death by 41 percent compared to Sorafini"The results of the IMbrave150 study are an important milestone in the treatment of patients with advanced liver cancer, one of the few cancers with increased mortality and limited choice of first-line treatment options
," said DrRichard Finn, a professor of medicine at the University of California, Los Angeles School of Medicine,"
" Is the first program since 2007 to improve the survival rate of sorafenib, a first-line treatment standard for hepatocellular carcinoma"

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.